We’re excited to back ModernVivo, an AI-native platform reinventing how in vivo studies are designed and run. By turning trial-and-error into precision, ModernVivo helps R&D teams design smarter, faster, and more ethical preclinical studies, cutting timelines and boosting translational success. Their AI models optimize animal studies for real-world outcomes, bridging the gap between lab and clinic.
ModernVivo caught our attention for their rethink of how in vivo studies are designed, a pain point often accepted as “just the way things are”. By addressing flawed preclinical protocols at the source, they’re empowering scientists to build stronger foundations for translational success.
Cedric Odje, Investment Associate at Debiopharm Innovation Fund
One of the big problems with drug development is the issue of translatability from in vitro tests through in vivo animal studies and on into the clinic. We are very excited to invest in Modern Vivo who bring their AI-driven solution for superior in vivo study design.
Tom Gibbs, Senior Investment Director at Debiopharm Innovation Fund
At ModernVivo, we are incredibly excited to partner with the Debiopharm Innovation Fund. This investment not only deepens our relationship with pharmaceutical companies doing groundbreaking research but accelerates our global presence. Their support will be crucial as we continue to improve and expand the development of our technology.
Ian Levine, CEO of ModernVivo